Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Ethiopian Government Strives to Increase Local Production of Drugs

By Frost & Sullivan | April 7, 2016

Government offers tax incentives to increase in-country production of medicines and improve healthcare, finds Frost & Sullivan.

The government of Ethiopia is offering tax and loan incentives to encourage local pharmaceutical production that will ultimately reduce the cost of drugs, increase job opportunities, improve economic growth, and enhance foreign exchange inflow.

Ethiopia has previously relied heavily on pharmaceutical imports—or international manufacturers with a footprint in the country—to meet a growing consumer demand for medicine. As a result, several initiatives will be rolled out to improve the quality of healthcare in the country, owing to a large gap in the supply and demand of drugs.

“The government has encouraged local pharmaceutical production with tax-free loans for up to five years and a 100 percent exemption on custom duty for imports on capital goods,” said Frost & Sullivan Industry Analyst for Transformational Health, Aditi Bhalla. “Furthermore, an income tax exemption for five years is provided to manufacturers exporting 50 percent of their products, or supplying 75 percent of their products or services as production or services input. The time for production registration has also been reduced to a month for local manufacturers.”

A new study from Frost & Sullivan, Analysis of the Ethiopian Pharmaceutical Market, finds that the market earned revenues of $620 million in 2015 and estimates this to reach $1.01 billion in 2020. The study covers prescription medicines and non-prescription, or over-the-counter (OTC), medicines. Prescription medicines are then further divided into generic and branded medicines.

Ethiopia has an increasing requirement of antibiotics, as well as anti-infective drugs, given the high incidences of communicable diseases in the country and an ever-growing population. This in turn is fueling the need for chronic care medication.

“In recent years, Ethiopia has increased its healthcare investments, resulting in a remarkable improvement in health indicators and achievement of health-related Millennium Development Goals,” observed Bhalla. “By delivering a host of incentives, the Government is addressing the needs of citizens, as well as encouraging trade across borders to bring in foreign exchange.”

In addition to rolling out programmes like the Growth and Transformational Plans (GTP-I, GTP-II) and Health Sector Development Plan, the Government has also partnered with the World Health Organisation. This collaboration has led to the launch of the National Strategy and Plan of Action for Pharmaceutical Manufacturing Development, which will urge domestic production and strengthen the national medicine regulatory system.

Analysis of the Ethiopian Pharmaceutical Market is part of the Life Sciences Growth Partnership Service program. Frost & Sullivan’s related studies include: Healthcare System Development in Tanzania and Ethiopia, An Overview of the South African National Development Plan 2030 and the Industrial Policy Action Plan, Global Next-generation Sequencing Trends, and Pharmaceutical Industry in Ghana and Nigeria. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

Distributed by APO (African Press Organization) on behalf of Frost & Sullivan.

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE